Advanced prostate cancer remains incurable with standard treatment options. Immunotherapy may be a realistic alternative given the growing evidence that the immune response can affect the growth of other solid tumours and the regulation of both speci®c and shared prostate cancer antigens. Early studies suggest that both non-speci®c and speci®c vaccines can effect relevant animal models and clinical trials based on these observations are now in progress. A number of other approaches including gene therapy with HSVtk are already undergoing clinical studies (Herman et al.
Introduction
There is a clear need for new therapeutic modalities for prostate cancer. The advent of prostate-speci®c antigen (PSA) testing has enabled prostate cancer to be diagnosed earlier and hopefully at a curable stage. However, although early localized disease is potentially curable by radical prostatectomy or radiotherapy, at least one-third of patients who undergo radical prostatectomy are subsequently found to have non-organ-con®ned disease on pathologic staging. Moreover, 35 ± 61% of patients receiving radical radiotherapy have positive post-irradiation prostatic biopsies. 2, 3 Therefore, a signi®cant proportion of patients treated with curative intent are left with residual disease. No adjuvant therapy or salvage therapy has been proven to be bene®cial for these men. In addition, despite the stage migration in prostate cancer in countries where PSA testing is widespread, a large proportion of men still present with advanced disease. Approximately 80 000 men in the USA were diagnosed with stage T3 prostate cancer in 1995. Since 1940, androgen ablation in the form of bilateral orchiectomy or, more recently, luteinizing hormone-releasing hormone (LHRH) analogues and antiandrogens have been the mainstay of treatment of metastatic prostate carcinoma. However, most patients show disease progression at 12 ± 18 months, and no therapy has been shown to prolong survival once the disease is hormone-resistant. Survival is typically 2 ± 3 y from the time of diagnosis of metastatic disease. 4 The limitations of current therapies have led investigators to look for other modalities, including immunotherapy and gene therapy. 5, 6 Prostate cancer and the immune system According to the immune surveillance theory of Burnet, the immune system is responsible for eliminating newly transformed cells. 7 Cases of spontaneous tumour regression, reported in melanoma and renal cell carcinoma, support the idea that the immune system is sometimes capable of delaying tumour progression and on rare occasions can eliminate the tumour completely. However, spontaneous regressions of prostate cancer are unknown and it has been regarded as an unlikely target for immunotherapy. Indeed, at one time it was thought that the prostate was an immunologically privileged site. 8 This was suggested on the basis that the prostate was lacking in lymphatics, but there is good evidence that the prostate has lymphatics and can mount an in¯ammatory response. 9, 10 More recently, it has been suggested that the immune response in prostate cancer may be associated with prognosis. In a Finnish series of 325 patients with prostate adenocarcinomas with long-term clinical follow-up data, the density of tumour-in®ltrating lymphocytes (TIL) was a prognostic factor independent of tumour grade, with absent or weak TIL being associated with a high risk of tumour progression. 11 It has been known for some time that patients with advanced prostate cancer have defective cell-mediated immunity. 12 Other observations include lower levels of interferon gamma (IFNg) in mitogen-stimulated blood cell cultures in patients with metastatic prostate cancer than in controls or patients with localized disease. 13 We recently showed that patients with advanced prostate cancer tend to have a predominantly Th2 cytokine pro®le within their peripheral blood mononuclear cells with a low proportion of cells producing IFNg and interleukin-2 (IL-2) and a higher proportion of cells secreting IL-4. 14 This suggests de®ciency in cellmedicated (Th-1) response.
Several studies demonstrate that prostate cancer may evade detection by the immune system by defective antigen presentation. Two of ®ve human metastatic prostate cancer cell lines were found to have defective class I major histocompatibility complex (MHC) cell surface expression. 15 A study of prostatic tissue from 47 patients with prostate cancer suggested that defective class expression is almost ubiquitous. 16 Complete loss of class I expression occurred in 34% of primary prostate cancers and 80% of lymph node metastases. Moreover, the downregulation was even more dramatic when individual class I allelic expression was analysed, occurring in 85% of primary prostate cancers and 100% of metastases. These ®ndings might explain why prostate cancers that progress fail to stimulate an immune response, but other mechanisms of immune escape described in other tumours may yet prove to be equally or more important. They include secretion of inhibitory substances, eg, tumour growth factor-beta (TGFb), IL-10, 17 abnormal T-lymphocyte signal transduction, 18 and expression by tumours of Fas ligand, which may enable tumour cells to induce apoptosis in Fas-expressing TIL. 19 Nevertheless, an improved outcome in BCG-treated prostate cancer patients has been reported in a randomized trial. 20 
Studies with Mycobacterium vaccae (M. vaccae)
Having noted that patients with metastatic melanoma who made an immune response to M. vaccae survived longer than those who did not, we investigated whether prostate cancer many be similarly susceptible. M. vaccae is a heat-killed mycobacterium which induces cell mediated immune responses in a similar manner to the BCG vaccine which is a live attenuated organism. In a pilot study of 10 patients, using cytokine production in vitro as a marker of immunological response and serum PSA as a marker of disease activity, two out of 10 patients had a PSA response as well as an increased cell mediated (Th-1) response. 14 We therefore explored the role of M. vaccae in the two rat prostate models, namely the Lobund ± Wistar rat within the PAIII cell line and the very aggressive MAT-Lylu line in the Copenhagen rat. M. vaccae was not effective by itself at delaying the rate of these tumours, but was an effective adjuvant to autologous tumour cells used as an irradiated vaccine prior to challenging with live tumour cells. 21 There was little effect in the treatment of established tumours (see Figure 1 ). We went on to explore the role of MHC-disparate (allogeneic) cell-based vaccines with and without adjuvants in the rat prostate models.
Allogeneic cell vaccines
We have previously shown that good appropriate celladjuvant combinations can be as effective as genetically transfected cells in the B16 and K1735 murine melanoma models. 22 Moreover, we clearly demonstrated that, contrary to expectations, allogeneic cell based vaccines were often superior to autologous vaccines in these models ( Figure 2 ). Apart from shared antigens, one reason for this is that`allogeneicity' represents a strong adjuvant danger signal' to the immune system. In further experiments we have shown the relevant antigens and the allo MHC must be expressed by the same cell.
The availability of rat models enabled us to explore the possibility of allogeneic vaccines in the prevention of rat prostate cancer. The results are more marked than the melanoma models with the allogeneic MAT-Lylu cell vaccine, giving 80% protection of Lobund ± Wistar rats challenged with PAIII. 23 The effect is only seen with PAIII vaccine and MAT-Lylu challenge with a more intensive vaccination schedule. However, this model is very aggressive and may simply outrun the immune response.
Human tumour antigens
The concept of active immunotherapy of cancer is based on the theory that tumours possess speci®c antigens, which can be recognized by the immune system. The term tumour-associated antigen (TAA) describes antigens found on human tumours that are also expressed on a small population of normal cells. It has become clear that self-proteins aberrantly expressed in tumours can activate CTLs. The majority of TAA have been identi®ed in melanoma cells, but they are beginning to be identi®ed in prostate cancer. One group of self-proteins commonly expressed in melanoma cells is the MAGE family. 24 These proteins are normally only expressed in the testis and placenta. Two other families, BAGE and GAGE, have a similar distribution of expression. A number of different tumour types have been found to express the MAGE, BAGE and GAGE genes. GAGE 7 and a novel gene designated PAGE, which has 45% homology to GAGE members, were found to be expressed in the metastatic prostate cancer cell line LNCaP. 25 More recently PAGE-I, a gene preferentially expressed in normal prostate, testis, fallopian tube, uterus and placenta, as well as in prostate cancer, testicular cancer and uterine cancer, has been described and may represent another yet undiscovered variant. 26 Further MAGE, BAGE and GAGE antigens are likely to be described in prostate cancer, but it remains to be seen if expression occurs in a suf®cient proportion of tumours for this class of Taos to be considered good immunotherapeutic targets in prostate cancer. Another group of TAAs includes tissue-speci®c proteins such as tyrosinase, Mart-1 gpl00, and gp75 in melanoma. 27 PSA and prostate-speci®c membrane antigen (PSMA) could be considered in the same category. It is unclear whether tolerance precludes CTL responses to self-proteins that are overexpressed in tumours. If tolerance to such antigens could be broken, it would have obvious implications for vaccine therapy in prostate cancer because PSA and PSMA are almost universally expressed by prostate adenocarcinomas. PSMA is a particularly attractive target because it is overexpressed in cancer cells as compared with benign cells. 28 The demonstration that within the Tcell repertoire there are populations of T cells that can be activated by certain peptide sequences within PSA (PSA 49 ± 63 and PSA 64 ± 78; 29 and PSA 141 ± 150 and PSA 154 ± 16 30 and within PSMA (PSMA 4 ± 12 31 is an important ®nding. These epitopes were MHC class I-restricted. Fortunately, the prostate gland has little physiologic relevance in postreproductive men and any autoimmune effects against normal prostate cells would be unlikely to cause harm. Several other candidate tumour antigens have been described, including TAG-72, an oncofoetal antigen expressed in 80% of prostate adenocarcinomas, 32 prostate carcinoma-associated glycoprotein complex (PAC), 33 and oncogenic antigen 519. 34 Mucins such as MUC-l are being investigated as potential target molecules for cancer immunotherapy in breast carcinoma and a number of other tumours, including prostate cancer. The reason is that not only is MUC-l upregulated in some tumours, it is also aberrantly glycosylated; therefore, tumour-associated mucin is distinct antigenically from the normal mucin. 35 Another advantage is that antigen presentation of MHC-1 to T-cells may not be MHC-restricted. This may be advantageous in prostate cancer, where class I MHC expression is often aberrant or downregulated. Beckett et al have described an antigen that is speci®c for prostate cancer and prostatic intraepithelial neoplasia (PIN). It has the structure of a mucin and has therefore been called`prostate mucin antigen' but its potential as an immunotherapeutic target has not been evaluated. 36, 37 The most comprehensive study thus far screened for expression of 30 different potential antigens in 11 primary and nine metastatic prostate cancer specimens and found considerable heterogeneity. The most commonly expressed antigens were GM2, KSA and MUC-2 in metastatic tumours, and PSMA-bhCG, Thompson-Friedenreich antigen (TF), Tn and sTn in primary tumours. 38 Of these, only PSMA was not expressed in normal tissues apart from prostate epithelium.
Another group of truly tumour-speci®c antigens that may be considered as potential targets consists of the products of genes such as mutated p53 and ras, which are different antigenic entities from their wild-type counterparts. H-ras mutations are an uncommon event (2 ± 5%) in prostate cancer. 40 ± 42 p53 mutations are uncommon in primary prostate cancers, 42, 43 but frequent in metastases of prostate cancer 44, 45 and in prostate cancer cell lines. 46 The clinical allogeneic prostate cancer vaccine trial at St George's Hospital, London
In view of the above studies, and in particular the encouraging protection seen in the allogeneic rat models, which has subsequently been shown to protect The ®gure shows that the rats esposed to the allogeneic vaccine survived twice as long as those exposed to the autologous vaccine. All rats in the control group died before 70 days.
The immunotherapy of prostate cancer AG Dalgleish et al in the aggressive Copenhagen model following minor alterations in the scheduling (Perry et al, unpublished observations), we set out to look for safety, immunological stimulation and potential ef®cacy in end stage patients with prostate cancer who had failed at least two endocrine treatment protocols. (In the latter stage of the study this was relaxed to one endocrine treatment protocol.) Eligible patients had to have a rising PSA of over 30 before enrolment. Sixty patients divided into four treatment arms, all of which contain three allogeneic cell lines, have now been recruited. Four different cell lines in various triplet combinations were used in conjunction with SRL-l72 M. vaccae as the adjuvant.
In order to maximize immunological information, a single cell line is given for the ®rst three injections following priming with the M. vaccae. The vaccines are given intradermally and the immune response is measured, ®rst of all using the cell lines in a DTH assay, followed by an in-depth serological analysis looking at antibodies to known as well as unknown antigens expressed by the cell lines. In particular we have been looking for broadening of responses to include antigens of cell lines not used in the vaccination. All patients have been monitored for their intracellular cytokine expression as we have previously used this assay to determine Th-1 (cell mediated) and Th-2 (humoural dominance) in patients with malignant melanoma, 47 where it was found that the majority of patients are Th-1 de®cient and that following vaccination or other immunotherapy, they may convert to being Th-1 dominant with a reduction in the Th-2 cytokine IL-4. When this occurred it was associated with an improved clinical outcome and survival.
In addition, we are performing proliferative studies against known antigens and antigens from a variety of prostate cell lines. Clinical assessment involves a quality of life-based study and regular monitoring of the prostate-speci®c antigen. Because of the advanced stage of these patients it is not ethically acceptable to deny other ongoing treatments such as radiotherapy for painful bone lesions. Results to date show no signi®cant toxicity, and immunological responses can clearly be demonstrated with all three modalities. In patients over half the immunological responses will be closely monitored in correlation with PSA responses and survival.
Since this study was initiated, a number of new cell lines have been raised by our group which appear to be more antigenic and probably more representative of both the primary prostate as well as secondary deposits than the four originally selected lines. These will also be tested following the completion of this study for the most optimal triplet to take forward into phase II studies. The absence of any side effects of this treatment would allow us to perform the next round of studies in patients with much better overall clinical status. It is planned to use the vaccine in selected patients with rising PSA following prostatectomy or radiotherapy prior to endocrine treatment. In addition, we are commencing a study giving the vaccine 3 weeks prior to prostatectomy in order to ascertain the immunological response in the prostate. This study will also compare the immune response to intra-prostate inoculation of allogeneic cells. Future studies will also involve the use of HSVtk (described below).
HSVtk
A number of genetic prodrug activation therapy (`suicide' gene therapy) approaches are being investigated as potential cancer therapies. We have been using herpes simplex virus thymidine kinase (HSVtk) in the two rat prostate cancer models, the Lobund ± Wistar and the Copenhagen rat 21, 48 described above. 49 HSVtk converts ganciclovir (the prodrug) into cytotoxic metabolites, and we showed that HSVtk-transfected tumours were killed with ganciclovir both in vitro, and in vivo (ectopic tumours; subcutaneous). Such in vivo destruction of tumours generated a tumour-speci®c Th1 immune response that was capable of destroying not only nontransfected tumour cells in the vicinity of the transfected cells but also non-transfected tumours at sites distant from the treatment: local and distal bystander effects, respectively. This means that such an approach could be useful against prostate cancer metastases as well as the primary tumour. We were able to successfully monitor HSVtk/ganciclovir treatment in situ, in vivo, using noninvasive magnetic resonance imaging and magnetic resonance spectroscopy. We are currently investigating ways of transferring the HSVtk gene to tumours in vivo, with adenoviral vectors being the main candidate.
If good promoters can be obtained (so that the HSVtk gene is only switched on in prostate cancer cells even if it does enter other cells), then it is possible to foresee a time when the HSVtk could be given intraprostate and the cancer completely killed with ganciclovir thus eliminating surgery and radiotherapy. The potential of this approach will initially be assessed by post-HSVtk ganciclovir treatment protatectomies, in order to quantitate the degree of local control. However, Baylor have already published a phase I dose escalation study in 18 patients using an adenovirus vector containing the HSVtk vector in which 13 patients achieved an objective response at the highest levels.
In conclusion
A number of immunotherapeutic approaches will be tried in the clinic over the coming years. In addition to the above approaches it should not be forgotten that antibodies to the HER/neu receptor have already been shown to be effective in breast cancer and the same receptor is expressed in cancer prostate cancer cells. The possible synergy between two or more of these approaches will doubtless be investigated if encouraging but limited ef®cacy is found in any one particular approach.
